Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APGE |
---|---|---|
09:32 ET | 3918 | 39.51 |
09:34 ET | 52715 | 40.195 |
09:36 ET | 900 | 40.39 |
09:38 ET | 12764 | 40.5 |
09:39 ET | 3987 | 40.145 |
09:41 ET | 1705 | 40.23 |
09:43 ET | 700 | 39.91 |
09:45 ET | 4198 | 40.11 |
09:48 ET | 3504 | 40.14 |
09:50 ET | 300 | 40.05 |
09:52 ET | 1400 | 40.08 |
09:54 ET | 4958 | 40.14 |
09:56 ET | 3080 | 39.97 |
09:57 ET | 1500 | 39.99 |
09:59 ET | 2858 | 40.05 |
10:01 ET | 3526 | 39.77 |
10:03 ET | 3883 | 39.95 |
10:06 ET | 100 | 39.88 |
10:08 ET | 400 | 39.89 |
10:10 ET | 5441 | 40.045 |
10:12 ET | 785 | 39.99 |
10:14 ET | 332 | 40 |
10:15 ET | 600 | 39.9 |
10:17 ET | 12349 | 40.08 |
10:19 ET | 1784 | 40.17 |
10:21 ET | 1200 | 40.18 |
10:24 ET | 32352 | 40.3 |
10:26 ET | 1100 | 40.3 |
10:28 ET | 2639 | 40.12 |
10:30 ET | 1100 | 39.84 |
10:32 ET | 1720 | 39.9 |
10:33 ET | 300 | 39.9 |
10:35 ET | 1494 | 39.91 |
10:37 ET | 7837 | 39.73 |
10:39 ET | 776 | 39.63 |
10:42 ET | 5801 | 39.45 |
10:44 ET | 400 | 39.2 |
10:46 ET | 1774 | 39.185 |
10:48 ET | 516 | 39.29 |
10:50 ET | 1000 | 39.335 |
10:51 ET | 1400 | 39.285 |
10:57 ET | 2073 | 39.14 |
11:00 ET | 200 | 39.01 |
11:02 ET | 2500 | 39.05 |
11:04 ET | 1750 | 38.975 |
11:06 ET | 1696 | 38.895 |
11:08 ET | 300 | 38.88 |
11:09 ET | 1730 | 38.9 |
11:11 ET | 3423 | 38.965 |
11:13 ET | 100 | 38.945 |
11:15 ET | 600 | 38.95 |
11:18 ET | 2203 | 38.96 |
11:20 ET | 200 | 38.975 |
11:22 ET | 5002 | 39.07 |
11:24 ET | 2200 | 39.21 |
11:26 ET | 400 | 39.165 |
11:27 ET | 1664 | 39.12 |
11:29 ET | 1274 | 39.06 |
11:31 ET | 1079 | 39.09 |
11:33 ET | 1000 | 39.09 |
11:36 ET | 900 | 39.13 |
11:38 ET | 300 | 39.1325 |
11:40 ET | 661 | 39.095 |
11:42 ET | 100 | 39.03 |
11:44 ET | 1994 | 39 |
11:45 ET | 610 | 39.02 |
11:47 ET | 3938 | 39.045 |
11:49 ET | 100 | 39.045 |
11:51 ET | 5082 | 38.75 |
11:54 ET | 1348 | 38.76 |
11:58 ET | 1461 | 38.8 |
12:00 ET | 100 | 38.77 |
12:02 ET | 2737 | 39.19 |
12:03 ET | 300 | 39.16 |
12:05 ET | 100 | 39.16 |
12:09 ET | 2408 | 38.94 |
12:12 ET | 699 | 38.81 |
12:14 ET | 300 | 38.76 |
12:16 ET | 2944 | 38.86 |
12:18 ET | 2820 | 38.915 |
12:20 ET | 768 | 38.92 |
12:21 ET | 600 | 38.99 |
12:23 ET | 450 | 38.995 |
12:25 ET | 1205 | 39.13 |
12:27 ET | 200 | 39.13 |
12:30 ET | 1296 | 39.22 |
12:32 ET | 300 | 39.22 |
12:34 ET | 1200 | 39.205 |
12:36 ET | 400 | 39.195 |
12:38 ET | 100 | 39.195 |
12:39 ET | 1495 | 38.96 |
12:41 ET | 690 | 38.89 |
12:43 ET | 694 | 38.905 |
12:45 ET | 400 | 38.76 |
12:48 ET | 1700 | 38.83 |
12:50 ET | 1029 | 38.83 |
12:56 ET | 500 | 38.82 |
12:57 ET | 1657 | 38.75 |
12:59 ET | 1045 | 38.83 |
01:01 ET | 200 | 38.75 |
01:03 ET | 1495 | 38.785 |
01:06 ET | 100 | 38.785 |
01:08 ET | 510 | 38.76 |
01:10 ET | 210 | 38.76 |
01:12 ET | 3078 | 38.85 |
01:15 ET | 300 | 38.85 |
01:17 ET | 100 | 38.855 |
01:19 ET | 200 | 38.8 |
01:21 ET | 300 | 38.8 |
01:24 ET | 1344 | 38.82 |
01:26 ET | 500 | 38.79 |
01:28 ET | 515 | 38.75 |
01:30 ET | 5964 | 38.58 |
01:32 ET | 2576 | 38.49 |
01:33 ET | 600 | 38.38 |
01:35 ET | 812 | 38.27 |
01:37 ET | 2000 | 38.34 |
01:39 ET | 200 | 38.33 |
01:42 ET | 100 | 38.36 |
01:44 ET | 900 | 38.28 |
01:46 ET | 2596 | 38.52 |
01:48 ET | 500 | 38.53 |
01:50 ET | 300 | 38.57 |
01:51 ET | 1500 | 38.52 |
01:53 ET | 300 | 38.48 |
01:55 ET | 1500 | 38.525 |
01:57 ET | 800 | 38.495 |
02:00 ET | 1575 | 38.48 |
02:02 ET | 1000 | 38.535 |
02:04 ET | 300 | 38.37 |
02:06 ET | 1828 | 38.45 |
02:08 ET | 100 | 38.505 |
02:09 ET | 1630 | 38.6 |
02:11 ET | 200 | 38.63 |
02:13 ET | 1551 | 38.85 |
02:15 ET | 300 | 38.84 |
02:18 ET | 1529 | 38.82 |
02:20 ET | 634 | 38.86 |
02:22 ET | 2004 | 38.82 |
02:24 ET | 300 | 38.82 |
02:26 ET | 500 | 38.82 |
02:27 ET | 808 | 38.87 |
02:29 ET | 1211 | 38.82 |
02:31 ET | 1453 | 38.91 |
02:33 ET | 755 | 38.95 |
02:36 ET | 1400 | 38.94 |
02:38 ET | 700 | 38.76 |
02:40 ET | 1416 | 38.79 |
02:42 ET | 707 | 38.86 |
02:44 ET | 100 | 38.85 |
02:45 ET | 455 | 38.83 |
02:47 ET | 600 | 38.84 |
02:49 ET | 1762 | 38.845 |
02:51 ET | 1890 | 38.81 |
02:54 ET | 583 | 38.57 |
02:56 ET | 1414 | 38.725 |
02:58 ET | 292 | 38.67 |
03:00 ET | 700 | 38.72 |
03:02 ET | 1782 | 38.715 |
03:03 ET | 1446 | 38.6 |
03:05 ET | 300 | 38.54 |
03:07 ET | 1147 | 38.63 |
03:09 ET | 1771 | 38.64 |
03:12 ET | 3210 | 38.67 |
03:14 ET | 700 | 38.66 |
03:16 ET | 900 | 38.665 |
03:18 ET | 1525 | 38.69 |
03:20 ET | 764 | 38.62 |
03:21 ET | 881 | 38.54 |
03:23 ET | 900 | 38.445 |
03:25 ET | 1800 | 38.425 |
03:27 ET | 687 | 38.37 |
03:30 ET | 1930 | 38.42 |
03:32 ET | 1200 | 38.32 |
03:34 ET | 575 | 38.23 |
03:36 ET | 3593 | 38.21 |
03:38 ET | 1144 | 38.24 |
03:39 ET | 1710 | 38.3 |
03:41 ET | 504 | 38.26 |
03:43 ET | 3688 | 38.475 |
03:45 ET | 3519 | 38.4325 |
03:48 ET | 1898 | 38.36 |
03:50 ET | 2745 | 38.25 |
03:52 ET | 5949 | 38.58 |
03:54 ET | 5042 | 38.56 |
03:56 ET | 7232 | 39 |
03:57 ET | 4888 | 39.02 |
03:59 ET | 21292 | 39.35 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Apogee Therapeutics Inc | 2.2B | -19.3x | --- |
Iovance Biotherapeutics Inc | 2.3B | -4.4x | --- |
Structure Therapeutics Inc | 2.2B | -16.9x | --- |
Celldex Therapeutics Inc | 2.4B | -13.0x | --- |
CG Oncology Inc | 2.0B | -28.0x | --- |
Janux Therapeutics Inc | 2.1B | -34.2x | --- |
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.04 |
Book Value | $7.86 |
P/E Ratio | -19.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.